Mojtaba Shafiee1, Mahsa Ahmadnezhad2, Maryam Tayefi3, Soheil Arekhi4, Hassanali Vatanparast5, Habibollah Esmaeili6, Mohsen Moohebati7, Gordon A Ferns8, Naghmeh Mokhber9, Seyed Rafie Arefhosseini10, Majid Ghayour-Mobarhan11. 1. Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: mojtaba.shafiee2@gmail.com. 2. Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Nutrition Research Center, Department of Community Nutrition, Tabriz University of Medical Sciences, Tabriz, Iran. 3. Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Metabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 4. Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Evidence Based Medicine Research Group, Mashhad University of Medical Sciences, Mashhad, Iran. 5. College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada. 6. Department of Biostatistics & Epidemiology, Faculty of Health, Management & Social Determinants of Health Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. 7. Cardiovascular Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. 8. Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK. 9. Psychiatry and Behavioral Sciences Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Iran. 10. Department of Nutritional Biochemistry, Tabriz University of Medical Sciences, Tabriz, Iran. Electronic address: ghayourm@mums.ac.ir. 11. Metabolic Syndrome Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: arefhosseini@gmail.com.
Abstract
BACKGROUND: Depression and anxiety are significantly associated with systemic inflammation. Moreover, oxidative stress resulting from a disturbance in the prooxidant-antioxidant balance is linked to inflammation-related conditions. Therefore, depression/anxiety symptoms may also be associated with oxidative stress. OBJECTIVE: To examine the association between depression/anxiety symptoms and serum prooxidant-antioxidant balance (PAB) in adults who participated in a large population-based, cross-sectional study. METHODS: Serum PAB values were measured in 7516 participants (62% females and 38% males) aged 35-65 years, enrolled in a population-based cohort study. beck depression and anxiety inventories were used to evaluate symptoms of depression and anxiety. Multinomial logistic regression was used to examine the effect of confounders on the status of serum PAB change. RESULTS: Among men, serum PAB values were increased incrementally from 1.55 ± 0.47 to 1.59 ± 0.47, 1.69 ± 0.38, and 1.68 ± 0.38 in the no or minimal, mild, moderate and severe depression groups, respectively (Ptrend < 0.001). Serum PAB values also increased significantly across these four corresponding groups among women [1.70 ± 0.45, 1.73 ± 0.44, 1.75 ± 0.44, and 1.76 ± 0.40, (Ptrend = 0.005)]. About anxiety, serum PAB values increased significantly across the four groups in men (Ptrend = 0.02) but not in women (Ptrend = 0.2). The adjusted odds ratios for serum PAB values among men with severe depression and anxiety symptoms were 1.75 and 1.27, respectively. Moreover, the adjusted odds ratios for serum PAB values among women with severe depression and anxiety symptoms were 1.40 and 1.17, respectively. CONCLUSION: Symptoms of depression and anxiety appear to be associated with higher degrees of oxidative stress, expressed by higher serum PAB values.
BACKGROUND:Depression and anxiety are significantly associated with systemic inflammation. Moreover, oxidative stress resulting from a disturbance in the prooxidant-antioxidant balance is linked to inflammation-related conditions. Therefore, depression/anxiety symptoms may also be associated with oxidative stress. OBJECTIVE: To examine the association between depression/anxiety symptoms and serum prooxidant-antioxidant balance (PAB) in adults who participated in a large population-based, cross-sectional study. METHODS: Serum PAB values were measured in 7516 participants (62% females and 38% males) aged 35-65 years, enrolled in a population-based cohort study. beck depression and anxiety inventories were used to evaluate symptoms of depression and anxiety. Multinomial logistic regression was used to examine the effect of confounders on the status of serum PAB change. RESULTS: Among men, serum PAB values were increased incrementally from 1.55 ± 0.47 to 1.59 ± 0.47, 1.69 ± 0.38, and 1.68 ± 0.38 in the no or minimal, mild, moderate and severe depression groups, respectively (Ptrend < 0.001). Serum PAB values also increased significantly across these four corresponding groups among women [1.70 ± 0.45, 1.73 ± 0.44, 1.75 ± 0.44, and 1.76 ± 0.40, (Ptrend = 0.005)]. About anxiety, serum PAB values increased significantly across the four groups in men (Ptrend = 0.02) but not in women (Ptrend = 0.2). The adjusted odds ratios for serum PAB values among men with severe depression and anxiety symptoms were 1.75 and 1.27, respectively. Moreover, the adjusted odds ratios for serum PAB values among women with severe depression and anxiety symptoms were 1.40 and 1.17, respectively. CONCLUSION: Symptoms of depression and anxiety appear to be associated with higher degrees of oxidative stress, expressed by higher serum PAB values.
Authors: Abbas Ali Sangouni; Sara Beigrezaei; Shahab Akbarian; Majid Ghayour-Mobarhan; Emad Yuzbashian; Amin Salehi-Abargouei; Gordon A Ferns; Sayyed Saeid Khayyatzadeh Journal: BMC Public Health Date: 2022-06-11 Impact factor: 4.135
Authors: Alisa S Cosan; Julietta U Schweiger; Kai G Kahl; Bettina Hamann; Michael Deuschle; Ulrich Schweiger; Anna L Westermair Journal: Brain Behav Date: 2020-11-05 Impact factor: 2.708